Delving into the Latest Updates on BAY-1237592 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

sGC

Action-

Mechanism

sGC stimulants(Soluble guanylate cyclase stimulants)

Therapeutic Areas

Respiratory DiseasesOther Diseases

Active Indication

Chronic thromboembolic pulmonary hypertensionPulmonary Arterial Hypertension

Inactive Indication-

Originator Organization

Bayer AG

Active Organization

Bayer AG

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

A Non-randomized Two Part Multi-center, Open-label, Single Dose Trial With an Escalation Part in Untreated Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Patients (Part A), Followed by a Parallel-group Part in Untreated and Pre-treated Patients With PAH and CTEPH (Part B) to Investigate the Safety, Tolerability and Pharmacodynamics of Inhaled BAY1237592

In this trial the effects of the inhaled drug BAY1237592 will be studied in patients with high blood pressure in the pulmonary blood vessels due to Pulmonary Arterial Hypertension (PAH) and due to Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Pulmonary hypertension is characterized by the elevation of pressure in the pulmonary arteries (PAP) and of the pulmonary vascular resistance (PVR) leading to increased workload of the right chamber of the heart to eject blood against this elevated resistance. The goal of this study is to measure the safety and tolerability of the drug as well as the reduction of the PVR at different doses
In Part A patients without specific treatment for PH (untreated patients) will be tested. In Part B also patients stably pre-treated with specific PH drugs will be studied in combination with the new inhaled drug

Start Date21 Jan 2019

Sponsor / Collaborator

Bayer AG

100 Clinical Results associated with BAY-1237592

Login to view more data

100 Translational Medicine associated with BAY-1237592

Login to view more data

100 Patents (Medical) associated with BAY-1237592

Login to view more data

100 Deals associated with BAY-1237592

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic thromboembolic pulmonary hypertension	Phase 1	Czechia	Bayer AG	21 Jan 2019
Chronic thromboembolic pulmonary hypertension	Phase 1	Austria	Bayer AG	21 Jan 2019
Chronic thromboembolic pulmonary hypertension	Phase 1	Poland	Bayer AG	21 Jan 2019
Chronic thromboembolic pulmonary hypertension	Phase 1	Germany	Bayer AG	21 Jan 2019
Pulmonary Arterial Hypertension	Phase 1	Austria	Bayer AG	21 Jan 2019
Pulmonary Arterial Hypertension	Phase 1	Germany	Bayer AG	21 Jan 2019
Pulmonary Arterial Hypertension	Phase 1	Poland	Bayer AG	21 Jan 2019
Pulmonary Arterial Hypertension	Phase 1	Czechia	Bayer AG	21 Jan 2019